Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Sequential treatment with two different commercially approved BCMA CAR-T products (ide-cel -> cilta-cel) is both feasible and effective, particularly in patients with prolonged responses to initial BCMA CAR-T therapy.”
Title: Sequential BCMA CAR-T Cell Therapy in Refractory Multiple Myeloma
Authors: Tim Richardson, Udo Holtick, Jan Hendrik Frenking, Hishan Tharmaseelan, Hyatt Balke-Want, Ruth Flümann, Elias K Mai, Sandra Sauer, Raphael Teipel, Malte von Bonin, Michael Hallek, Christoph Scheid, Philipp Gödel
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski in OncoDaily.
